Therapeutic phlebotomy, the controlled removal of blood to treat disease, is alive and well in modern medicine. It is not a fringe holdover from the barber-surgeon era but a first-line treatment for a handful of serious conditions, prescribed by hematologists and performed in hospitals and blood centers around the world. The practice looks nothing like the indiscriminate bleeding of centuries past, yet the core idea is the same: sometimes taking blood out of the body is the most effective way to fix what is going wrong inside it.
What Changed Between Then and Now
Historical bloodletting was applied to nearly every ailment imaginable, from fevers to melancholy, on the theory that illness reflected an imbalance of bodily fluids. That theory was wrong, and bloodletting fell out of favor once germ theory and modern pharmacology arrived. What survived was a narrow set of conditions where removing blood addresses a specific, measurable problem: too much iron in the body or too many red blood cells. Modern therapeutic phlebotomy targets those problems with defined goals, usually a specific lab value the doctor wants to bring down to a safe range. A typical session removes roughly one unit of blood (about 450–500 mL), much like a standard blood donation, though the schedule can be far more aggressive than what a volunteer donor would experience.
Hereditary Hemochromatosis
The single biggest reason doctors still prescribe blood removal is hereditary hemochromatosis, a genetic condition in which the body absorbs too much iron from food. Over years, the excess iron deposits in the liver, heart, pancreas, and joints, eventually causing organ damage if left unchecked. The fix is straightforward: remove blood at regular intervals, forcing the body to use up stored iron to manufacture new red blood cells. The goal is to bring ferritin, the blood marker for iron stores, down to a level between roughly 20 and 50 micrograms per liter.
For people with very heavy iron overload (total body iron above about 30 grams), that process can mean weekly sessions lasting two to three years before iron levels reach target.
The good news is that when hemochromatosis is caught before organs are damaged, the prognosis with phlebotomy is excellent.
Once iron stores are normalized, patients typically shift to a maintenance schedule of a few sessions per year, enough to keep iron from creeping back up. The therapy does not cure the underlying genetic tendency; it simply keeps the consequences at bay. Some patients find the ongoing commitment burdensome, and iron chelation drugs exist as an alternative for those who cannot tolerate phlebotomy, though phlebotomy remains the standard of care.
Polycythemia Vera
Polycythemia vera is a blood cancer in which the bone marrow overproduces red blood cells, thickening the blood and raising the risk of clots, strokes, and heart attacks. All patients with polycythemia vera need phlebotomy to keep their hematocrit (the percentage of blood volume occupied by red cells) below 45 percent, typically alongside low-dose aspirin.
For younger, lower-risk patients, phlebotomy alone may be enough. For higher-risk patients, it is usually combined with a drug called hydroxyurea that slows marrow production. Even with hydroxyurea on board, some patients still need frequent phlebotomies. Research shows that patients who require three or more sessions a year on top of hydroxyurea face a higher risk of blood clots than those who need fewer, suggesting that the continued need for phlebotomy signals more aggressive disease.
Though phlebotomy prevents life-threatening cardiovascular events and prolongs survival in polycythemia vera, it does not necessarily make patients feel better day to day. Fatigue, dizziness after sessions, and the time commitment of repeated clinic visits weigh on quality of life, and researchers continue to explore whether newer drugs can reduce the phlebotomy burden without sacrificing safety.
Porphyria Cutanea Tarda
A less well-known but textbook use of phlebotomy is porphyria cutanea tarda, a condition in which porphyrins (chemicals involved in making heme, the iron-containing part of hemoglobin) build up in the skin and liver, causing painful blistering and skin fragility in sun-exposed areas. Iron plays a key role in driving porphyrin overproduction, so depleting iron stores through phlebotomy brings the biochemistry back under control.
In studies, patients who underwent regular phlebotomy saw their urinary porphyrin levels drop to normal within a few months, and skin symptoms cleared roughly in step with the biochemical improvement. Remission lasted years in many patients, though relapse could occur once iron stores crept back up. A comparison trial found that phlebotomy and an injectable iron-chelation drug achieved equivalent results, but phlebotomy was simpler to perform and remained the preferred treatment.
Other Accepted Indications
Beyond those three main conditions, phlebotomy shows up in smaller niches. Adults with certain forms of cyanotic congenital heart disease can develop dangerously high red-cell counts as the body tries to compensate for chronically low oxygen levels. In those patients, phlebotomy is reserved for relieving symptoms of hyperviscosity, the sluggish blood flow that comes with extremely thick blood, rather than being used routinely.
Phlebotomy is also sometimes used in secondary iron overload, which affects people who receive many blood transfusions for conditions like sickle cell disease or thalassemia, though chelation drugs are more common in that setting. The unifying principle across all these uses is the same: the blood contains too much of something (iron or red cells), and removing blood is the most direct way to bring it down.
What a Session Actually Looks Like
If you have never been through one, a therapeutic phlebotomy session feels a lot like donating blood. A needle goes into a vein, usually in the arm, and blood flows into a collection bag. The session takes roughly 15 to 30 minutes. Patients are monitored for drops in blood pressure and encouraged to drink fluids afterward. The main difference from a standard blood donation is the frequency: therapeutic patients can be phlebotomized on a much tighter schedule than volunteer donors, sometimes weekly, under a physician’s orders.
Side effects are generally mild. Lightheadedness, fatigue, and bruising at the needle site are common. The more significant concern with repeated sessions is iron-deficiency anemia. In conditions like polycythemia vera, a degree of iron depletion is actually the goal, since it slows red-cell production. But for some patients the resulting fatigue and weakness become a real quality-of-life problem, and managing that trade-off is one of the trickier aspects of long-term phlebotomy.
Can Phlebotomy Blood Be Used for Transfusion?
An interesting policy question surrounds what happens to the blood that is drawn. In a standard blood donation, the unit goes to someone who needs a transfusion. Blood removed therapeutically has historically been discarded in many countries, partly because the donation is medically motivated rather than voluntary, and partly out of concern that iron-overloaded blood might carry higher infection risk.
A systematic review of the evidence found no reason to believe that blood from uncomplicated hemochromatosis patients, once iron levels are normalized, is unsafe for transfusion, and called for countries to harmonize their policies to allow it. A global survey of blood services found that about two-thirds of responding centers already accept hemochromatosis patients as donors, though rules vary widely: some allow more frequent donations than regular donors, while most require a prescription or approval from the patient’s treating physician. The trend is toward broader acceptance, which makes practical sense given chronic shortages in many blood banks.
Medicinal Leeches, a Related Survivor
Leeches are the other relic of pre-modern bloodletting that made it into the modern hospital, though their role is completely different from phlebotomy. Medicinal leeches are FDA-approved devices used in plastic and reconstructive surgery to relieve venous congestion in grafted tissue. When a surgical flap has good arterial blood flowing in but poor venous drainage flowing out, it swells with deoxygenated blood and risks dying. Attaching a leech provides temporary drainage and, just as usefully, delivers natural anticoagulant compounds from the leech’s saliva that keep blood flowing through the affected tissue while new veins grow in.
The main indications are venous congestion and hematoma after reconstructive procedures. In a case series of 23 patients treated with leeches, just over half were treated for venous congestion and about 40 percent for hematoma. Leech therapy can also protect free flaps against ischemia-reperfusion injury and clot formation. The treatment looks medieval, but the biology behind it is well understood and the results are often hard to replicate any other way.
Experimental Territory and the NAFLD Question
Researchers have been probing whether phlebotomy might help in conditions beyond its established uses, and the most actively studied frontier involves metabolic liver disease. Non-alcoholic fatty liver disease (NAFLD) is associated with disrupted iron metabolism, and some investigators hypothesized that depleting iron through phlebotomy could improve insulin resistance, liver enzyme levels, and even the fatty changes visible on liver biopsy.
The results so far are mixed. Some smaller studies found that iron depletion corrected insulin resistance and improved blood lipids, apparently independent of changes in body weight. But a randomized controlled trial of 274 patients with dysmetabolic iron overload syndrome, a metabolic subtype closely related to NAFLD, found that bloodletting did not improve metabolic or liver features, was associated with weight gain, and was not as well tolerated as expected. The study’s authors concluded that sustained changes in diet and exercise remain the first-line intervention for these patients.
A broader review of the evidence concluded that while some metabolic markers may improve with iron depletion, there is near-universal agreement that phlebotomy does not improve liver tissue itself in NAFLD. One study noted that fatigue occurred roughly ten times more often in patients undergoing phlebotomy than in controls. For now, phlebotomy for fatty liver disease remains experimental and is not part of standard clinical guidelines.
Wet Cupping and Traditional Bloodletting Practices
Outside the walls of Western hospitals, bloodletting traditions persist in several cultures. Wet cupping (known as hijama in Arabic medical tradition) involves making small incisions in the skin and applying suction cups to draw out a small amount of blood. It is practiced widely across parts of the Middle East, South Asia, and East Asia, both in traditional medicine settings and in integrative clinics in Western countries.
A systematic review of randomized trials found promising evidence for wet cupping in musculoskeletal pain, including nonspecific low back pain, neck pain, and carpal tunnel syndrome, but called for better-quality research before firm conclusions could be drawn. The volumes of blood removed are tiny compared with therapeutic phlebotomy, so the mechanism, if real, likely involves local effects like stimulating blood flow, triggering an inflammatory healing response, or a placebo component rather than the systemic iron or red-cell reduction that makes phlebotomy work for hemochromatosis or polycythemia vera. The two practices share an ancestor but have essentially nothing in common from a physiological standpoint.
When Phlebotomy Falls Short
For all its effectiveness, phlebotomy has real limitations. A Delphi consensus survey of experts treating hemochromatosis found that side effects and the impact on quality of life make the therapy troublesome for a meaningful number of patients. Iron-deficiency symptoms, especially fatigue, can paradoxically mirror the symptoms of the disease being treated. The time commitment of weekly or biweekly sessions during the initial depletion phase disrupts work and daily life. Some patients with poor venous access find the procedure itself difficult.
Alternatives exist for patients who cannot tolerate phlebotomy. Iron chelation drugs, which bind iron and allow it to be excreted, are an option for hemochromatosis patients, though these drugs carry their own side-effect profiles. Erythrocytapheresis, a procedure that selectively removes red blood cells while returning plasma to the patient, can achieve iron depletion or hematocrit reduction more efficiently per session, though it requires specialized equipment and is less widely available. For polycythemia vera specifically, newer targeted drugs like ruxolitinib are being studied for their ability to reduce phlebotomy dependence, and pegylated interferon is gaining traction as a treatment that may modify the disease itself rather than just managing symptoms.
Why the Old Practice Survived
The persistence of phlebotomy in modern medicine is sometimes held up as a curiosity, as if doctors are stubbornly clinging to a medieval technique. The reality is more interesting. Phlebotomy survived because it targets a problem that no pill replaces efficiently: physically removing excess iron or excess red cells from the circulation. Iron chelation drugs work, but they are expensive, carry side effects of their own, and still do not remove iron as quickly as directly draining blood. For polycythemia vera, no drug has yet been shown to be a safe substitute for keeping hematocrit below the critical threshold. The treatment endured not out of nostalgia but because the human body has no built-in mechanism for excreting large amounts of iron. Once iron gets in, the only fast way out is with the blood it is riding in.
That mechanical simplicity is also what keeps the cost low. A phlebotomy session requires a needle, a collection bag, and a trained phlebotomist. Compared with the price of specialty drugs or apheresis machines, it is remarkably affordable, which matters for conditions that require lifelong management. In an era when new therapies routinely cost thousands of dollars per month, the fact that the most effective treatment for a common genetic disorder is essentially the same as giving blood carries a certain quiet appeal.